IMMUNOPHARMACOLOGICAL MONITORING OF CYCLOSPORIN A‐TREATED RECIPIENTS OF CADAVERIC KIDNEY ALLOGRAFTS

No abstract is available for this paper.

• Publication year

  1982

• Venue

  Transplantation

• Publication date

  1982-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00007890-198207000-00007PMID 6214878
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunological evaluation of transplant rejection: pre and postoperative indices detecting immune responsiveness.

  1981cited by this paper
• Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts.

  1981cited by this paper
• Differential effects of cyclosporin-A on lymphocyte subpopulations.

  1981cited by this paper
• INHIBITION OF HUMAN NATURAL KILLER ACTIVITY BY CYCLOSPORIN A

  1981cited by this paper
• CORRELATION OF NONSPECIFIC IMMUNE MONITORING WITH REJECTION OR IMPAIRED FUNCTION OF RENAL ALLOGRAFTS

  1981cited by this paper
• Natural cell-mediated cytotoxicity in long-term kidney transplant recipients.

  1981cited by this paper
• Cyclosporin A in cadaveric organ transplantation.

  1981cited by this paper
• Effect of cyclosporin A on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR.

  1980cited by this paper
• Effects of cyclosporin A on suppressor and inducer T lymphocytes in primary biliary cirrhosis.

  1980cited by this paper
• Cyclosporin receptor on mouse lymphocytes.

  1980cited by this paper
• IMPROVED ALLOGRAFT SURVIVAL OF STRONG IMMUNE RESPONDER‐HIGH RISK RECIPIENTS WITH ADJUVANT ANTITHYMOCYTE GLOBULIN THERAPY

  1980cited by this paper
• Current concepts in immunology: Regulation of the immune response--inducer and suppressor T-lymphocyte subsets in human beings.

  1980cited by this paper
• Monoclonal antibodies defining distinctive human T cell surface antigens.

  1979cited by this paper
• Selective effects of cyclosporin A on colony-forming lymphoid and myeloid cells in man

  1979cited by this paper
• Macrophage-related suppressor cells in human renal transplant recipients.

  1979cited by this paper
• Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers.

  1979cited by this paper
• Cyclosporin A in patients receiving renal allografts from cadaver donors.

  1978cited by this paper
• The suppressor-cell network in cancer (first of two parts).

  1978cited by this paper
• Effects of the new anti-lymphocytic peptide cyclosporin A in animals.

  1977cited by this paper
• Suppression of lymphoproliferation by high concentrations of normal human mononuclear leukocytes.

  1977cited by this paper
• Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity.

  1976cited by this paper

• What's New in Psoriasis.

  2019cites this paper
• Identification of the Genotype – Phenotype Correlation in the Inosine Monophosphate Dehydrogenase Enzyme

  2012cites this paper
• Evolution of Liver Transplantation

  2007cites this paper
• therapy with cyclosporine for cardiac transplantation

  2005cites this paper
• Therapeutic drug monitoring for everolimus in kidney transplantation using 12‐month exposure, efficacy, and safety data

  2005cites this paper
• TRANSPLANTATION OF TIE HEART Immunosuppressive therapy with cyclosporine for cardiac transplantation

  2005cites this paper
• Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation

  2005cites this paper
• Neoral C2 monitoring in maintenance liver transplant patients: A step forward?

  2004cites this paper
• Análise do nível sangüíneo ideal de ciclosporina no pós-transplante renal precoce

  2004cites this paper
• Neoral C2 monitoring in solid organ transplantation.

  2004cites this paper
• Abstracts of the NIH-FDA Conference “Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications”

  2002cites this paper
• Cyclosporine: role of pharmacokinetics

  2001cites this paper
• Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity

  2000cites this paper
• Neoral/cyclosporine-based immunosuppression.

  1999cites this paper
• Considerations concerning generic formulations of immunosuppressive drugs.

  1999cites this paper
• Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome.

  1999cites this paper
• Two‐hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy 1

  1998cites this paper
• Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients.

  1998cites this paper
• Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy.

  1998cites this paper
• Comparison between enzyme-linked immunosorbent assay and cytotoxic cross-match procedures for detecting IgG anti-donor antibodies.

  1998cites this paper
• Improved graft survival in 100 retransplant recipients following AHG-negative crossmatching.

  1997cites this paper
• Retransplantation following AHG-negative crossmatches

  1997cites this paper
• Rapid, sensitive high-performance liquid chromatographic method for the determination of cyclosporin A and its metabolites M1, M17 and M21.

  1997cites this paper
• Postrenal transplant MLR hypo-responders have fewer rejections and better graft survival than MLR hyper-responders.

  1997cites this paper
• Neoral in liver transplantation.

  1996cites this paper
• The panorama of cyclosporin research

  1996cites this paper
• The impact of elevated serum IgA and race on primary recipient renal allograft survival.

  1996cites this paper
• To keep a stable therapeutic level of cyclosporine during the early posttransplant period is important in graft survival.

  1996cites this paper
• Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection.

  1996cites this paper
• Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation.

  1996cites this paper
• Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals.

  1995cites this paper
• Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).

  1995cites this paper
• Are corticosteroids really necessary in renal transplantation?

  1995cites this paper
• Chronic immunosuppression of the renal transplant patient.

  1994cites this paper
• Is there a relation between cycloporine trough levels and endomyocardial biopsy score after heart transplantation?

  1994cites this paper
• Therapeutic monitoring of cyclosporine.

  1994cites this paper
• Clinical Biochemistry and Transplantation Surgery

  1994cites this paper
• The effect of transfusion with donor-specific peripheral lymphocytes, whole blood or erythrocytes on cardiac allograft survival in cyclosporine-treated rats.

  1994cites this paper
• Influence of HLA matching on rejections and short- and long-term primary cadaveric allograft survival.

  1993cites this paper
• Immune risk factors: impact on the incidence and diagnosis of rejection.

  1993cites this paper
• Optimization of cyclosporine therapy.

  1993cites this paper
• Pharmacokinetic model for subcutaneous absorption of cyclosporine in the rabbit during chronic treatment.

  1992cites this paper
• Pharmacodynamic Monitoring of Cyclosporin

  1992cites this paper
• Retrospective study of renal transplantation with cyclosporine (CyA) monotherapy--the importance of CyA blood trough levels on long-term graft survival.

  1992cites this paper
• AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival.

  1991cites this paper
• Synergistic and antagonistic effects of combinations of cyclosporine A and its metabolites on inhibition of phytohemagglutinin-induced lymphocyte transformation in vitro.

  1991cites this paper
• Improved renal allograft survival for AHG and DTE/AHG crossmatch-negative recipients.

  1991cites this paper
• Stronger immune responsiveness of blacks vs whites may account for renal allograft survival differences.

  1991cites this paper
• Interleukin‐2 receptor gene expression in kidney transplant recipients treated with cyclosporin A

  1991cites this paper
• Analytical performance of EMIT cyclosporine assay evaluated.

  1991cites this paper
• Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients.

  1991cites this paper
• Preemptive transplantation--an analysis of benefits and hazards in 85 cases.

  1991cites this paper
• The impact of steady-state cyclosporine concentrations on renal allograft outcome.

  1990cites this paper
• Comparison of the utility of 3H-based specific monoclonal antibody assay on whole blood samples with the fluorescence polarization nonspecific immunoassay on serum samples for diagnosis of adverse events in renal transplant patients.

  1990cites this paper
• Onset and Development of Cyclosporin A Effects on Lymphocytes of Cardiac Patients Before Heart Transplantation

  1990cites this paper
• anadian ConsensusMeetingon Cyclosporine Monitoring: Reportof the ConsensusPanel

  1990cites this paper
• Cyclosporin a and renal function in renal transplant recipients.

  1990cites this paper
• Summary on therapeutic drug monitoring for renal transplantation.

  1990cites this paper
• The development of clinical renal transplantation.

  1990cites this paper
• Improved graft survival for flow cytometry and antihuman globulin crossmatch-negative retransplant recipients.

  1990cites this paper
• Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine.

  1990cites this paper
• Immunologic monitoring of steroid withdrawal in renal allograft recipients on triple therapy with cyclosporine‐A, azathioprine and prednisone

  1990cites this paper
• Interaction of intravenous methylprednisolone with oral cyclosporin.

  1990cites this paper
• Canadian Consensus Meeting on cyclosporine monitoring: report of the consensus panel.

  1990cites this paper
• IMPROVED IMMUNOSUPPRESSION FOR HEART TRANSPLANT PATIENTS USING INTRAVENOUS DOSES OF CYCLOSPORINE

  1989cites this paper
• Advances in cyclosporine pharmacology, measurement, and therapeutic monitoring.

  1989cites this paper
• The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients.

  1989cites this paper
• Optimal cyclosporin levels during the first month after cadaveric kidney transplantation. Leuven Collaborative Group for Transplantation.

  1989cites this paper
• Liver transplantation: an update for physicians.

  1989cites this paper
• Cyclosporine A.

  1989cites this paper
• Acute Renal Failure and Toxic Nephropathy

  1989cites this paper
• Cyclosporin A nephrotoxicity.

  1989cites this paper
• Drug Induced Renal Effects of Cyclosporine, Aminoglycoside Antibiotics and Lithium: Extrapolation of Animal Data to Man

  1989cites this paper
• Evaluation of cyclosporine nephrotoxicity by renal transplant fine needle aspiration.

  1989cites this paper
• Cyclosporine in dermatology.

  1989cites this paper
• Combination therapy of cyclosporine with steroid inhibits γ-interferon and interleukin-1 gene expression at the level of mRNA synthesisin vivo

  1989cites this paper
• Improved liquid-chromatographic determination of cyclosporine and its metabolites in blood.

  1988cites this paper
• Intravenous cyclosporine to induce immunosuppression in cardiac allograft recipients.

  1988cites this paper
• Analysis of rejection in cyclosporine-treated cardiac allograft recipients.

  1988cites this paper
• Successful transplantation of 100 untransfused cyclosporine-treated primary recipients of cadaveric renal allografts.

  1988cites this paper
• Impact of blood transfusions and HLA on cyclosporine-treated renal transplant recipients.

  1988cites this paper
• Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood.

  1988cites this paper
• Absorption profiles of renal allograft recipients receiving oral doses of cyclosporine: a pharmacokinetic study.

  1988cites this paper
• Cyclosporine levels are not helpful.

  1988cites this paper
• CYCLOSPORINE PLASMA LEVELS SIX HOURS AFTER ORAL ADMINISTRATION: A Useful Tool For Monitoring Therapy

  1988cites this paper
• Comparison and correlation of assays for monitoring cyclosporine drug levels in renal transplant recipients.

  1988cites this paper
• THE IMPACT OF HLA A, B, AND DR BLOOD TRANSFUSIONS AND IMMUNE RESPONDER STATUS ON CARDIAC ALLOGRAFT RECIPIENTS TREATED WITH CYCLOSPORINE

  1988cites this paper
• Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy.

  1988cites this paper
• Siklosporine Bağli Nefrotoksisite

  1988cites this paper
• Subcutaneous absorption of cyclosporine in rabbits.

  1988cites this paper
• Cyclosporine dose adjustment in patients with normal serum creatinine and trough levels: a challenge for successful long-term treatment.

  1988cites this paper
• THE IN VIVO IMMUNOSUPPRESSIVE ACTION OF SUPPRESSOR CELLS FROM ALLOANTIGEN‐CYCLOSPORINE-TREATED MICE AND THE CAPACITY OF SPLEEN CELLS TO RELEASE INTERLEUKINS AND -INTERFERON1

  1988cites this paper
• Serum cyclosporine kinetic profile. Failure to correlate with nephrotoxicity or rejection episodes following sequential immunotherapy for renal transplantation.

  1988cites this paper
• [Pharmacological characteristics of cyclosporin A. Its use in kidney transplantation].

  1988cites this paper
• Parent-to-child transplantation with cyclosporine immunosuppression.

  1987cites this paper
• INVESTIGATION OF HTLV‐3 SEROLOGY IN A RENAL TRANSPLANT POPULATION

  1987cites this paper
• "In vivo effects of rIL-2 pretreatment on chemotherapeutically induced in vivo natural cytolytic hyporesponsiveness".

  1987cites this paper
• MULTIVARIATE ANALYSIS OF RISK FACTORS IMPACTING ON IMMEDIATE AND EVENTUAL CADAVER ALLOGRAFT SURVIVAL IN CYCLOSPORINE‐TREATED RECIPIENTS

  1987cites this paper
• Risk factors for cadaveric donor allograft survival in cyclosporine-prednisone-treated recipients.

  1987cites this paper
• Is cyclosporine administration in twice daily dose advantageous?

  1987cites this paper